View Item 

Show simple item record

Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management
dc.contributor.authorFeng, Sandy
dc.contributor.authorBucuvalas, John C.
dc.contributor.authorMazariegos, George V.
dc.contributor.authorMagee, John C.
dc.contributor.authorSanchez‐fueyo, Alberto
dc.contributor.authorSpain, Katharine M.
dc.contributor.authorLesniak, Andrew
dc.contributor.authorKanaparthi, Sai
dc.contributor.authorPerito, Emily
dc.contributor.authorVenkat, Veena L.
dc.contributor.authorBurrell, Bryna E.
dc.contributor.authorAlonso, Estella M.
dc.contributor.authorBridges, Nancy D.
dc.contributor.authorDoo, Edward
dc.contributor.authorGupta, Nitika A.
dc.contributor.authorHimes, Ryan W.
dc.contributor.authorIkle, David
dc.contributor.authorJackson, Annette M.
dc.contributor.authorLobritto, Steven J.
dc.contributor.authorJose Lozano, Juan
dc.contributor.authorMartinez, Mercedes
dc.contributor.authorNg, Vicky L.
dc.contributor.authorRand, Elizabeth B.
dc.contributor.authorSherker, Averell H.
dc.contributor.authorSundaram, Shikha S.
dc.contributor.authorTurmelle, Yumirle P.
dc.contributor.authorWood‐trageser, Michele
dc.contributor.authorDemetris, Anthony J.
dc.date.accessioned2021-05-12T17:25:01Z
dc.date.available2022-06-12 13:25:00en
dc.date.available2021-05-12T17:25:01Z
dc.date.issued2021-05
dc.identifier.citationFeng, Sandy; Bucuvalas, John C.; Mazariegos, George V.; Magee, John C.; Sanchez‐fueyo, Alberto ; Spain, Katharine M.; Lesniak, Andrew; Kanaparthi, Sai; Perito, Emily; Venkat, Veena L.; Burrell, Bryna E.; Alonso, Estella M.; Bridges, Nancy D.; Doo, Edward; Gupta, Nitika A.; Himes, Ryan W.; Ikle, David; Jackson, Annette M.; Lobritto, Steven J.; Jose Lozano, Juan; Martinez, Mercedes; Ng, Vicky L.; Rand, Elizabeth B.; Sherker, Averell H.; Sundaram, Shikha S.; Turmelle, Yumirle P.; Wood‐trageser, Michele ; Demetris, Anthony J. (2021). "Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management." Hepatology (5): 1985-2004.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/167499
dc.publisherWiley Periodicals, Inc.
dc.titleEfficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167499/1/hep31520_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167499/2/hep31520.pdf
dc.identifier.doi10.1002/hep.31520
dc.identifier.sourceHepatology
dc.identifier.citedreferenceSoltys KA, Mazariegos GV, Squires RH, Sindhi RK, Anand R, Split Research Group. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant 2007; 7: 2165 - 2171.
dc.identifier.citedreferenceLi Y, Zhao X, Cheng D, Haga H, Tsuruyama T, Wood K, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008; 86: 1837 - 1843.
dc.identifier.citedreferenceScheenstra R, Peeters PM, Verkade HJ, Gouw AS. Graft fibrosis after pediatric liver transplantation: ten years of follow- up. Hepatology 2009; 49: 880 - 886.
dc.identifier.citedreferenceWozniak LJ, Hickey MJ, Venick RS, Vargas JH, Farmer DG, Busuttil RW, et al. Donor- specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation 2015; 99: 1416 - 1422.
dc.identifier.citedreferenceAberg F, Isoniemi H, Pukkala E, Jalanko H, Rasmussen A, Storm HH, et al. Cancer after liver transplantation in children and young adults: a population- based study from 4 nordic countries. Liver Transpl 2018; 24: 1252 - 1259.
dc.identifier.citedreferenceMartinelli J, Habes D, Majed L, Guettier C, Gonzales E, Linglart A, et al. Long- term outcome of liver transplantation in childhood: a study of 20- year survivors. Am J Transplant 2018; 18: 1680 - 1689.
dc.identifier.citedreferenceMemaran N, Borchert- Morlins B, Schmidt BMW, Sugianto RI, Wilke H, Blote R, et al. High burden of subclinical cardiovascular target organ damage after pediatric liver transplantation. Liver Transpl 2019; 25: 752 - 762.
dc.identifier.citedreferenceRuebner RL, Reese PP, Denburg MR, Abt PL, Furth SL. End- stage kidney disease after pediatric nonrenal solid organ transplantation. Pediatrics 2013; 132: e1319 - e1326.
dc.identifier.citedreferenceFeng S, Bucuvalas J. Tolerance after liver transplantation: where are we? Liver Transpl 2017; 23: 1601 - 1614.
dc.identifier.citedreferenceLevitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol 2018; 79: 283 - 287.
dc.identifier.citedreferenceUemura T, Ikegami T, Sanchez EQ, Jennings LW, Narasimhan G, McKenna GJ, et al. Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 2008; 22: 316 - 323.
dc.identifier.citedreferenceThurairajah PH, Carbone M, Bridgestock H, Thomas P, Hebbar S, Gunson BK, et al. Late acute liver allograft rejection; a study of its natural history and graft survival in the current era. Transplantation 2013; 95: 955 - 959.
dc.identifier.citedreferenceLevitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol 2017; 15: 584 - 593.e582.
dc.identifier.citedreferenceJadlowiec CC, Morgan PE, Nehra AK, Hathcock MA, Kremers WK, Heimbach JK, et al. Not all cellular rejections are the same: differences in early and late hepatic allograft rejection. Liver Transpl 2019; 25: 425 - 435.
dc.identifier.citedreferenceBenitez C, Londono MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58: 1824 - 1835.
dc.identifier.citedreferenceFeng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283 - 293.
dc.identifier.citedreferenceShaked A, DesMarais MR, Kopetskie H, Feng S, Punch JD, Levitsky J, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am J Transplant 2019; 19: 1397 - 1409.
dc.identifier.citedreferenceLiver Transpl Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transplant 2012; 18: 1154 - 1170.
dc.identifier.citedreferenceBonaccorsi- Riani E, Pennycuick A, Londono MC, Lozano JJ, Benitez C, Sawitzki B, et al. Molecular characterization of acute cellular rejection occurring during intentional immunosuppression withdrawal in liver transplantation. Am J Transplant 2016; 16: 484 - 496.
dc.identifier.citedreferenceBohne F, Martinez- Llordella M, Lozano JJ, Miquel R, Benitez C, Londono MC, et al. Intra- graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122: 368 - 382.
dc.identifier.citedreferenceVenturi C, Sempoux C, Bueno J, Ferreres Pinas JC, Bourdeaux C, Abarca- Quinones J, et al. Novel histologic scoring system for long- term allograft fibrosis after liver transplantation in children. Am J Transplant 2012; 12: 2986 - 2996.
dc.identifier.citedreferenceDemetris AJ, Bellamy C, Hubscher SG, O’Leary J, Randhawa PS, Feng S, et al. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody- mediated rejection. Am J Transplant 2016; 16: 2816 - 2835.
dc.identifier.citedreferenceNg VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varni JW, et al. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr 2012; 160: 820 - 826.e823.
dc.identifier.citedreferenceWong YC, Tay SS, McCaughan GW, Bowen DG, Bertolino P. Immune outcomes in the liver: Is CD8 T cell fate determined by the environment? J Hepatol 2015; 63: 1005 - 1014.
dc.identifier.citedreferenceLondono MC, Souza LN, Lozano JJ, Miquel R, Abraldes JG, Llovet LP, et al. Molecular profiling of subclinical inflammatory lesions in long- term surviving adult liver transplant recipients. J Hepatol 2018; 69: 626 - 634.
dc.identifier.citedreferenceCampbell PM, Senior PA, Salam A, Labranche K, Bigam DL, Kneteman NM, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007; 7: 2311 - 2317.
dc.identifier.citedreferenceHricik DE, Formica RN, Nickerson P, Rush D, Fairchild RL, Poggio ED, et al. Adverse outcomes of tacrolimus withdrawal in immune- quiescent kidney transplant recipients. J Am Soc Nephrol 2015; 26: 3114 - 3122.
dc.identifier.citedreferenceJucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, et al. Prevalence and impact of de novo donor- specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients. Hepatology 2019; 69: 1273 - 1286.
dc.identifier.citedreferenceWiebe C, Gibson IW, Blydt- Hansen TD, Pochinco D, Birk PE, Ho J, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor- specific antibody. Am J Transplant 2015; 15: 2921 - 2930.
dc.identifier.citedreferenceHodges AM, Lyster H, McDermott A, Rice AJ, Smith JD, Rose ML, et al. Late antibody- mediated rejection after heart transplantation following the development of de novo donor- specific human leukocyte antigen antibody. Transplantation 2012; 93: 650 - 656.
dc.identifier.citedreferenceLe Pavec J, Suberbielle C, Lamrani L, Feuillet S, Savale L, Dorfmuller P, et al. De- novo donor- specific anti- HLA antibodies 30 days after lung transplantation are associated with a worse outcome. J Heart Lung Transplant 2016; 35: 1067 - 1077.
dc.identifier.citedreferenceTaner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, et al. Prevalence, course and impact of HLA donor- specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504 - 1510.
dc.identifier.citedreferenceO’Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, et al. The role of donor- specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779 - 787.
dc.identifier.citedreferenceFeng S, Demetris AJ, Spain KM, Kanaparthi S, Burrell BE, Ekong UD, et al. Five- year histological and serological follow- up of operationally tolerant pediatric liver transplant recipients enrolled in WISP- R. Hepatology 2017; 65: 647 - 660.
dc.identifier.citedreferenceDel Bello A, Congy- Jolivet N, Danjoux M, Muscari F, Kamar N. Donor- specific antibodies and liver transplantation. Hum Immunol 2016; 77: 1063 - 1070.
dc.identifier.citedreferenceVandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon- Augoyard C, et al. Prevalence, risk factors, and impact of donor- specific alloantibodies after adult liver transplantation. Liver Transpl 2018; 24: 1091 - 1100.
dc.identifier.citedreferenceTodo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, et al. A pilot study of operational tolerance with a regulatory T cell- based cell therapy in living donor liver transplantation. Hepatology 2016; 64: 632 - 643.
dc.identifier.citedreferenceCrispe IN. Immune tolerance in liver disease. Hepatology 2014; 60: 2109 - 2117.
dc.identifier.citedreferenceJackson AM, Kanaparthi S, Burrell BE, Lucas DP, Vega RM, Demetris AJ, et al. IgG4 donor- specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients. Am J Transplant 2020; 20: 513 - 524.
dc.identifier.citedreferenceLevitsky J, Burrell BE, Kanaparthi S, Turka LA, Kurian S, Sanchez- Fueyo A, et al. Immunosuppression withdrawal in liver transplant recipients on sirolimus. Hepatology 2019 Nov 13. https://doi.org/10.1002/hep.31036. [Epub ahead of print]
dc.identifier.citedreferenceWong T, Nouri- Aria KT, Devlin J, Portmann B, Williams R. Tolerance and latent cellular rejection in long- term liver transplant recipients. Hepatology 1998; 28: 443 - 449.
dc.identifier.citedreferenceHeymann F, Peusquens J, Ludwig- Portugall I, Kohlhepp M, Ergen C, Niemietz P, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 2015; 62: 279 - 291.
dc.identifier.citedreferenceTaubert R, Danger R, Londono MC, Christakoudi S, Martinez- Picola M, Rimola A, et al. Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated. Am J Transplant 2016; 16: 1285 - 1293.
dc.identifier.citedreferenceEkong UD, Melin- Aldana H, Seshadri R, Lokar J, Harris D, Whitington PF, et al. Graft histology characteristics in long- term survivors of pediatric liver transplantation. Liver Transpl 2008; 14: 1582 - 1587.
dc.identifier.citedreferenceEvans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006; 43: 1109 - 1117.
dc.identifier.citedreferenceFeng S, Bucuvalas JC, Demetris AJ, Burrell BE, Spain KM, Kanaparthi S, et al. Evidence of chronic allograft injury in liver biopsies from long- term pediatric recipients of liver transplants. Gastroenterology 2018; 155: 1838 - 1851.e1837.
dc.identifier.citedreferenceGuerra MR, Naini BV, Scapa JV, Reed EF, Busuttil RW, Cheng EY, et al. Obliterative portal venopathy: a histopathologic finding associated with chronic antibody- mediated rejection in pediatric liver allografts. Pediatr Transplant 2018; 22: e13124.
dc.identifier.citedreferenceHerzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl 2008; 14: 946 - 955.
dc.identifier.citedreferenceMiyagawa- Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor- specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333 - 1342.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep31520_am.pdf
Size:
1.309MB
Format:
PDF
View/Open
Name:
hep31520.pdf
Size:
1.634MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.